GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2013

Cytori Taps Medistem Technology for Autoimmune Disease Drug Development

  • San Diego, CA-based Cytori Therapeutics is using Medistem’s patented “Stem Cell Mediated Treg Activation” technology to develop autoimmune disease treatments.

    Under the terms of the agreement, Cytori gains a license and exclusive rights to use Medistem technology outlined in U.S. Patent No. 8,241,621. Cytori will use Medistem technology in efforts related to its Adipose-Derived Regenerative Cell-based platform for the treatment of autoimmune diseases. Financial terms were not disclosed.

    “We are delighted to have formalized a licensing agreement with an adult stem cell leader like Cytori and look forward to working with them in the future,” Medistem CEO Alan J. Lewis, Ph.D., said in a statement.

    Added Cytori’s Marc H. Hedrick, president: “We are pleased to have licensed this patent from Medistem because it strengthens our patent portfolio in the area of immune disease.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?